Positive Phase III data for Radius Health's abaloparatide in postmenopausal osteoporosis

The results of a Phase III trial of abaloparatide, from US pharma company Radius Health (Nasdaq: RDUS), suggest it significantly reduces fractures in postmenopausal women with osteoporosis at 18 months when compared with placebo.

These positive results from the 2,463-patient, Phase III ACTIVE trial have been published in the Journal of the American Medical Association (JAMA), and showed fewer new vertebral and non-vertebral fractures in the abaloparatide arm after 18 months of treatment.

Paul Miller, medical director at the Colorado Center for bone research and lead author of the paper, said: “The landmark ACTIVE trial results are important and further validate abaloparatide’s potential to consistently, substantially and rapidly reduce both new vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.